Supplemental Table 1. Baseline characteristics of included subjects (n, 111)

|  |  |  |  |
| --- | --- | --- | --- |
|  | Variables |  | Values |
| Demographics | Male sex |  | 65 (59%) |
|  | Age (years) |  | 71 ± 12 |
|  | Dependency before stroke |  | 19 (17%) |
| Vascular risk factors | Hypertension |  | 84 (74%) |
|  | Diabetes |  | 29 (26%) |
|  | Dyslipidemia |  | 36 (32%) |
|  | Smoking |  | 50 (45%) |
|  | Atrial fibrillation |  | 63 (57%) |
|  | Antiplatelets before stroke |  | 43 (39%) |
|  | Anticoagulants before stroke |  | 12 (11%) |
|  | Statins before stroke |  | 29 (26%) |
| Laboratory information | Hematocrit (%) |  | 41.3 ± 5.1 |
|  | Random glucose (mg/dL) |  | 133 ± 48 |
|  | Hb A1c (%) |  | 6.0 ± 0.9 |
|  | Total cholesterol (mg/dL) |  | 167 ± 43 |
|  | Systolic blood pressure (mm Hg) |  | 149 ± 24 |
| Stroke-related information | LSN to arrival (minutes) |  | 533 [446 - 621] |
|  | Wake-up stroke |  | 53 (48%) |
|  | NIHSS score |  | 14 [10 - 19] |
|  | Infarct volume |  | 28.6 [11.0 - 71.7] |
|  | Mismatch ratio |  | 2.5 [1.2 - 5.6] |
|  | Mismatch ratio ≥ 1.8 |  | 64 (58%) |
|  | Favorable image profile by DEFUSE 2 |  | 47 (42%) |
|  | Location of occlusion | Extracranial ICA | 28 (25%) |
|  |  | Intracranial ICA | 7 (6%) |
|  |  | MCA | 76 (69%) |
| Stroke treatments | Endovascular recanalization treatment |  | 60 (54%) |
|  | Preceding IV tPA |  | 8 (7%) |
|  | mTICI score 2b or 3 |  | 46 (77%) |
|  | Primary recanalization devices | Solitaire | 45 (75%) |
|  |  | Trevo | 10 (17%) |
|  |  | Others | 5 (8%) |
|  | Puncture to recanalization (minutes) |  | 37 [21 - 84] |
|  | LSN to recanalization (minutes) |  | 664 [565 - 735] |
|  | Procedure time (minutes) |  | 57 (30 - 107) |
| Outcomes | Hemorrhagic transformation | Any HT | 43 (39%) |
|  |  | PH2 | 7 (6%) |
|  | mRS score 0 - 1 at 3 months |  | 21 (19%) |
|  | Mortality until 3 months |  | 16 (14%) |

\* LSN, last seen normal; NIHSS, National Institutes of Health Stroke Scale; ICA, internal carotid artery; MCA, middle cerebral artery; IV tPA, intravenous tissue plasminogen activator; mTICI, modified thrombolysis in cerebral infarction; HT, hemorrhagic transformation; PH2, parenchymal hemorrhage 2; mRS, modified Rankin Scale